CDK4 and breast cancer: Dalpiciclib is a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor that plays a key role in hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER-2)-negative breast cancer.